This suggests that there is a switch from ERα-dependent to HER2-dependent and ERα-independent expression of FOXM1 when patients progress under endocrine treatment, even in ER+ breast cancer cells that do not have HER2 amplification or activating HER2 mutations. Here, FOXM1 is linked to breast carcinoma.